Amgen, AstraZeneca Report Full Positive Phase 3 Tezepelumab Results
26 Februar 2021 - 4:14PM
Dow Jones News
By Colin Kellaher
Amgen Inc. and AstraZeneca PLC on Friday reported full positive
results from a pivotal Phase 3 trial of tezepelumab, a potential
treatment for patients with severe, uncontrolled asthma.
The companies said the study, dubbed "Navigator," showed
superiority versus placebo across every primary and key secondary
endpoint, with a statistically significant and clinically
meaningful reduction in the annualized asthma exacerbation rate in
severe, uncontrolled asthma patients.
Amgen and AstraZeneca said tezepelumab is the only biologic to
consistently and significantly reduce the exacerbation rate in a
broad population of severe asthma patients, and they noted that
results from the study will form the basis of regulatory filings
for the drug.
U.K. pharmaceutical giant AstraZeneca and Amgen, a Thousand
Oaks, Calif., biotechnology company, agreed in 2012 to collaborate
on tezepelumab.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 26, 2021 09:59 ET (14:59 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024